scholarly journals Alpha 1-Adrenoceptor Blocker May Improve Not Only Voiding But Also Storage Lower Urinary Tract Symptoms Caused by 125I Brachytherapy for Prostate Cancer

ISRN Urology ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Nobuyuki Oyama ◽  
Yoshitaka Aoki ◽  
Hideaki Ito ◽  
Yoshiji Miwa ◽  
Hironobu Akino ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
External Beam Radiation ◽  
Prostate Brachytherapy ◽  
Beam Radiation ◽  
Urinary Tract Symptoms ◽  
Postvoid Residual Urine ◽  
Lower Urinary

Purpose. To assess changes in lower urinary tract symptoms (LUTS) within 1 year after brachytherapy in patients receiving alpha 1-adrenoceptor antagonists. Methods. We retrospectively evaluated 116 patients who underwent 125I prostate brachytherapy in our institute. Seventy-one patients were treated with a combination of external beam radiation therapy and brachytherapy. Alpha 1-adrenoceptor antagonists were prescribed to all patients after brachytherapy. International Prostate Symptom Score (IPSS) forms and postvoid residual urine volume were recorded at all follow-up visits. Results. Forty-nine patients were given tamsulosin hydrochloride, 32 were given silodosin hydrochloride, and 35 were given naftopidil for up to 6 months after seed implantation. Patients given tamsulosin or naftopidil tended to show a higher peak IPSS and slower recovery to baseline values than those given silodosin. The patients given naftopidil showed an insufficient recovery in storage symptoms in naftopidil group in comparison with tamsulosin group at 3 months and with silodosin group at 6 and 9 months. Conclusions. In the management of LUT after brachytherapy, silodosin may provide a more favorable improvement. Silodosin and tamsulosin may have an advantage in improving not only voiding but also storage lower urinary tract symptoms after brachytherapy.

Possibilities of phytotherapy in patients with lower urinary tract symptoms due to benign prostate enlargement

2020 ◽  
Vol 10 (4) ◽  
pp. 317-323
Author(s):  
Adel S. Al-Shukri ◽  
Stanislav V. Kostyukov
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostate Gland ◽  
Urine Volume ◽  
Good Tolerability ◽  
Clinical Indicators ◽  
Urinary Tract Symptoms ◽  
Main Component ◽  
Lower Urinary

The results of the use of the phytopreparation Tadimax in the treatment of 60 men with mild and moderate lower urinary tract symptoms (LUTS) developed as a result of benign enlargement of the prostate gland are presented. The average age of the patients was 66.5 3.8 years. Tadimax was prescribed 2 tablets 3 times a day, in courses of 7 days with 7 day breaks for 3 months (a total of 6 courses). The data obtained indicate high efficacy and good tolerability of treatment. A decrease in the severity of LUTS was noted in 59 (96.6%) patients, which was accompanied by significant changes in objective clinical indicators: a decrease in residual urine volume and an increase in urine flow rate. Tadimax is a combined preparation, which includes extracts of several medicinal plants, and the main component is Crinum latifolium. The therapeutic effect of Tadimax is based on anti-inflammatory, antiproliferative and immunotropic action.

scholarly journals The reliability and reproducibility of ultrasonography for measuring the residual urine volume in men with lower urinary tract symptoms

2014 ◽  
Vol 12 (4) ◽  
pp. 285-289 ◽  
Author(s):  
Hassan A. Abdelwahab ◽  
Housseini M. Abdalla ◽  
Mahmoud H. Sherief ◽  
Mohamed B. Ibrahim ◽  
Mostafa A. Shamaa
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Prospective randomized controlled study directly comparing tadalafil and tamsulosin for male patients with lower urinary tract symptoms

2018 ◽  
Author(s):  
Takumi Takeuchi ◽  
Satoshi Toyokawa ◽  
Yumiko Okuno ◽  
Noriko Ishida ◽  
Masanari Yamagoe ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Maximum Flow ◽  
Controlled Study ◽  
Night Time ◽  
Once Daily ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

AbstractLower urinary tract symptoms are widespread in elderly men and often suggestive of benign prostatic hyperplasia (LUTS/BPH). A randomized, prospective, and open-labeled trial directly comparing the effects of tadalafil (a phosphodiesterase 5 inhibitor) 5 mg once daily and tamsulosin (an α1-blocker) 0.2 mg once daily for 12 weeks in LUTS/BPH patients was conducted. Data were recorded before randomization as well as at 4, 8, and 12 weeks after medication. Fifteen patients allocated tadalafil and 20 allocated tamsulosin completed 12 weeks of medication. Total IPSS, IPSS voiding, and IPSS-QOL scores declined with medication, but there was no difference between drugs. IPSS storage scores reduced more in the tamsulosin group than tadalafil group. OABSS did not decline significantly with medication. IIEF5 was maintained in the tadalafil group, but declined in the tamsulosin group. The maximum flow rate and post-void residual urine volume did not significantly change with medication. Daytime, night-time, and 24-hour urinary frequencies as well as the mean and largest daytime, night-time, and 24-hour voiding volumes per void did not significantly change with medication. In conclusion, tamsulosin was more effective to reduce storage symptoms than tadalafil. Tadalafil had the advantage of maintaining the erectile function.

scholarly journals The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Naoya Masumori ◽  
Taiji Tsukamoto ◽  
Masahiro Yanase ◽  
Hiroki Horita ◽  
Masaharu Aoki
Keyword(s):  
Urinary Tract ◽  
Overactive Bladder ◽  
Symptom Score ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Real Life ◽  
Benign Prostatic Obstruction ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Objectives. To investigate the add-on effect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-life clinical practice.Methods. Patients aged ≥ 50 having remaining OAB symptoms (≥ 3 of OAB symptom score (OABSS) with ≥2 of urgency score) after at least 4 weeks treatment by 0.2 mg of tamsulosin for BPO/LUTS received 2.5 or 5.0 mg of solifenacin for 12 weeks. The International Prostate Symptom Score (IPSS), QOL index and OABSS, maximum flow rate (Qmax) and postvoid residual urine volume (PVR) were determined.Results. A total of 48 patients (mean age 72.5 years) completed the study. There were significant improvement in IPSS (15.1 to 11.2) and QOL index (4.2 to 3.0) by add-on of solifenacin. Although the IPSS storage symptom score was significantly improved, there were no changes observed in the IPSS voiding symptom score. The OABSS showed significant improvement (8.0 to 4.8). No changes were observed in Qmax and PVR.Conclusions. Under the supervision of an experienced urologist, the additional administration of solifenacin to patients with BPO/LUTS treated with tamsulosin, is effective in controlling remaining OAB symptoms.

Impact of pre-implant lower urinary tract symptoms on postoperative urinary morbidity after permanent prostate brachytherapy

2012 ◽  
Vol 19 (12) ◽  
pp. 1083-1089 ◽  
Author(s):  
Jun Teishima ◽  
Hideo Iwamoto ◽  
Katsutoshi Miyamoto ◽  
Koichi Shoji ◽  
Hiroshi Masumoto ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostate Brachytherapy ◽  
Urinary Tract Symptoms ◽  
Urinary Morbidity ◽  
Lower Urinary
Sign in / Sign up

Export Citation Format

Share Document